Indeterminate Lesions clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
open to eligible people ages 18 years and up
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
at UCLA UCSD
Our lead scientists for Indeterminate Lesions research studies include Tara A. McCannel, MD, PhD.
Last updated: